» Articles » PMID: 3552280

Tumor Hypoxia: Its Impact on Cancer Therapy

Overview
Specialty Oncology
Date 1987 Jan 1
PMID 3552280
Citations 85
Authors
Affiliations
Soon will be listed here.
Abstract

The presence of radiation resistant cells in solid human tumors is believed to be a major reason why radiotherapy fails to eradicate some such neoplasms. The presence of unperfused regions containing hypoxic cells may also contribute to resistance to some chemotherapeutic agents. This paper reviews the evidence that radiation resistant hypoxic cells exist in solid tumors, the assumptions and results of the methods used to detect hypoxic cells, and the causes and nature of tumor hypoxia. Evidence that radiation resistant hypoxic cells exist in the vast majority of transplanted rodent tumors and xenografted human tumors is direct and convincing, but problems with the current methodology make quantitative statements about the magnitude of the hypoxic fractions problematic. Evidence that radiation resistant hypoxic cells exist in human tumors is considerably more indirect than the evidence for their existence in transplanted tumors, but it is convincing. However, evidence that hypoxic cells are a significant cause of local failure after optimal clinical radiotherapy or chemotherapy regimens is limited and less definitive. The nature and causes of tumor hypoxia are not definitively known. In particular, it is not certain whether hypoxia is a chronic or a transient state, whether hypoxic cells are proliferating or quiescent, or whether hypoxic cells have the same repair capacity as aerobic cells. A number of new methods for assessing hypoxia are reviewed. While there are still problems with all of the new techniques, some of them have the potential of allowing the assessment of hypoxia in individual human tumors.

Citing Articles

Recent advances in spatio-temporally controllable systems for management of glioma.

Zhang H, Zhu W, Pan W, Wan X, Li N, Tang B Asian J Pharm Sci. 2024; 19(5):100954.

PMID: 39483717 PMC: 11525460. DOI: 10.1016/j.ajps.2024.100954.


Fe-doped nanodiamond-based photo-Fenton catalyst for dual-modal fluorescence imaging and improved chemotherapeutic efficacy against tumor hypoxia.

Selvam R, Pearl W, Perevedentseva E, Karmenyan A, Cheng C RSC Adv. 2024; 14(6):4285-4300.

PMID: 38298935 PMC: 10828792. DOI: 10.1039/d3ra08465e.


Insights into the function of cytoglobin.

Reeder B Biochem Soc Trans. 2023; 51(5):1907-1919.

PMID: 37721133 PMC: 10657185. DOI: 10.1042/BST20230081.


DNA Damage Inducer Mitoxantrone Amplifies Synergistic Mild-Photothermal Chemotherapy for TNBC via Decreasing Heat Shock Protein 70 Expression.

Chen Z, Li S, Li F, Qin C, Li X, Qing G Adv Sci (Weinh). 2023; 10(16):e2206707.

PMID: 37066748 PMC: 10238214. DOI: 10.1002/advs.202206707.


Effect of intensity modulated radiotherapy on lymphocytes in patients with esophageal squamous cell carcinoma and its clinical significance.

Tian X, Hou Y, Guo J, Wu H, Nie L, Wang H Front Oncol. 2023; 13:1096386.

PMID: 36959779 PMC: 10028288. DOI: 10.3389/fonc.2023.1096386.


References
1.
LITTBRAND B, EDSMYR F . Preliminary results of bladder carcinoma irradiated with low individual doses and a high total dose. Int J Radiat Oncol Biol Phys. 1976; 1(11-12):1059-62. DOI: 10.1016/0360-3016(76)90076-6. View

2.
Moore J, Hasleton P, Buckley C . Tumour cords in 52 human bronchial and cervical squamous cell carcinomas: inferences for their cellular kinetics and radiobiology. Br J Cancer. 1985; 51(3):407-13. PMC: 1976955. DOI: 10.1038/bjc.1985.55. View

3.
GRAY L . Radiobiologic basis of oxygen as a modifying factor in radiation therapy. Am J Roentgenol Radium Ther Nucl Med. 1961; 85:803-15. View

4.
Hermens A, Barendsen G . Changes of cell proliferation characteristics in a rat rhabdomyosarcoma before and after x-irradiation. Eur J Cancer (1965). 1969; 5(2):173-89. DOI: 10.1016/0014-2964(69)90065-6. View

5.
HOWARD-FLANDERS P, Alper T . The sensitivity of microorganisms to irradiation under controlled gas conditions. Radiat Res. 1957; 7(5):518-40. View